New hope for kids with tough cancers: testing a targeted drug

NCT ID NCT04925609

Summary

This study is testing a drug called brigatinib in children and young adults (ages 1 to under 26) with specific cancers that have a genetic change called ALK-positive. The cancers include anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and other solid tumors that have come back or not responded to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will see how well the drug works at controlling these cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institut Gustave Roussy

    RECRUITING

    Paris, 94805, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Princess Máxima Center for Pediatric Oncology

    RECRUITING

    Utrecht, Utrecht, 3584 CS, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.